Could this mark a shift in how we think about cancer therapy? At least in the laboratory, evidence suggests it may be.

The cancer gene MYC camouflages tumours by suppressing alarm signals that normally activate the immune system. This finding ...

Inovio Pharmaceuticals faces an October 30 PDUFA date for INO-3107 with high regulatory risk and only a 5-7 month cash runway. Read why INO stock is a hold.

A new study led by researchers at the Johns Hopkins Kimmel Cancer Center, its Bloomberg~Kimmel Institute for Cancer ...

Trained immunity enhances innate immune responses, yet a Western lifestyle may lead to maladaptive trained immunity and drive ...

The main objective of this randomized, double-blind, placebo-controlled study was to measure the impact of a multivitamin supplement on nutrient status and quality of life (QOL) and compare two ...

Research led by Lancaster University has discovered that a class of antibiotics—fluoroquinolones—can directly alter the ...

Cancer evolves through layers of change: mutations in DNA, shifts in gene regulation, altered cell behaviour, and dynamic ...

As Dr. Christopher Bellavita observed in his 2008 article "Changing Homeland Security: What is Homeland Security?", "The ...

Reshaping the Global Drug Development Landscape with the Industry's Only Natively AI-Powered Omnimodal Foundation Model for Tumor and Immune Biology ...

32 Biosciences, a gastrointestinal (GI)-focused biotechnology company pioneering gut mucosal-immune science to prevent and treat GI diseases, today announced that it will officially launch its $40 ...

BridGene Biosciences, Inc., a leader in the discovery of small-molecule drugs for traditionally "hard-to-drug" targets, announced today the appointment of Bruce A. Beutler, M.D., Nobel Prize–winning ...